The S&P 500 (+0.3%), Nasdaq Composite (+0.5%), and Dow Jones Industrial Average (+0.02%) closed at record highs on Friday, even as President Trump said he had not yet agreed to roll back existing tariffs. The Russell 2000 increased 0.3%.
President Trump's statement refuted China's claim that an agreement was already made, but the market maintained an optimistic view on trade. It presumably continued to think that a "Phase One" deal will still get signed considering the president didn't technically rule out the possibility to roll back tariffs and White House trade advisor Peter Navarro said the U.S. might be willing to delay the Dec. 15 tariffs.
There still wasn't much conviction from buyers or sellers for most of the session, though, until a wave of buyers pushed the market to session highs into the close. The S&P 500 health care (+0.8%) and information technology (+0.6%) sectors posted decent gains, while the energy (-0.8%), utilities (-0.4%), and real estate (-0.2%) sectors finished lower.
Walt Disney (DIS 137.96, +5.00, +3.8%) beat earnings estimates and shares of the Dow component rose accordingly. Its outperformance also helped the S&P 500 communication services sector (+0.4%) overcome weakness in Verizon (VZ 59.35, -1.18, -2.0%), which fell on no confirmed new catalyst.
The trade-sensitive Philadelphia Semiconductor Index (+0.5%) continued to rise amid the upbeat trade sentiment. The group also benefited from follow-through buying in shares of Qualcomm (QCOM 94.03, +4.05, +4.5%) after it reported positive earnings results earlier in the week.
In other corporate news, Southwest's (LUV 58.18, -0.06, -0.1%) 10-Q stated it plans to remove Boeing's (BA 351.00, -6.31, -1.8%) 737 MAX from its flight schedule through March 6, 2020. This is a one-month delay. Gap, Inc. (GPS 16.68, -1.38, -7.6%) announced the departure of its CEO and issued downside EPS guidance.
The U.S. Treasury market finished relatively unchanged in a quiet session. The 2-yr yield declined one basis point to 1.66%, and the 10-yr yield increased one basis point to 1.93%. The U.S. Dollar Index increased 0.2% to 98.37. WTI crude increased 0.2% (+$0.10) to $57.21/bbl.
Reviewing Friday's economic data, which included the preliminary University of Michigan Consumer Sentiment Index for November and the Wholesale Inventories report for September:
- The preliminary University of Michigan Consumer Sentiment Index for November crossed at 95.7 (consensus 95.0), which was slightly better than expected and roughly even with the final reading of 95.5 for October.
- The key takeaway from the report is that consumer expectations increased from October, underscoring an otherwise confident attitude that should continue to manifest itself in relatively solid consumer spending activity.
- Wholesale inventories declined 0.4% m/m in September (consensus -0.1%), on top of a downwardly revised 0.1% increase (from +0.2%) in August. That was the largest decline since October 2017. Wholesale sales were flat in September after declining 0.1% in August.
- The key takeaway from the report is that it could prove difficult for wholesalers to gain pricing power given that inventory growth remains well ahead of sales growth on a yr/yr basis.
Investors will not receive any notable economic data on Monday.
- Nasdaq Composite +27.7% YTD
- S&P 500 +23.4% YTD
- Dow Jones Industrial Average +18.7% YTD
- Russell 2000 +18.6% YTD
In reaction to disappointing earnings/guidance:
- MED -28.4%, TDC -25.5% (also Teradata names Victor Lund interim CEO following departure of Oliver Ratzesberger), MOD -19.8%, GDOT -17.9%, NVEE -15.2% (issues correction regarding FY20 guidance; guidance now in-line with analyst estiamate) RGR -15.1%, ALTR -14.6%, TIVO -12.3%, HEAR -11%, SCPL -9.6%, CWH -9.2%, TUSK -9.1%, ENLC -5%, UPLD -4.9%, ARLO -4.6%, SVMK -4.3%, LPSN -3.5%, MTD -2.9%, MGA -2.9%, MITK -2.6%, GSBD -2.4%, PEGA -2.4%, CTRE -2.2%, KRO -2.1%, TTD -1.9%, TRHC -1.9%, PEN -1.7%, ATVI -1.7%, BE -1.6%, USCR -1.4%, COLD -1.2%, NWSA -1.2%, TTWO -0.8%
Other news:
- AFMD -11.4% (prices public offering of 12 mln common shares at a public offering price of $2.50 per common share)
- ADMS -10.6% (files $200 mln mixed securities shelf offering; reports Q3 results)
- GPS -8.9% (names Chairman Robert Fisher to as interim CEO, sees Q3 EPS below consensus)
- LXRX -5.4% (files $150 mln mixed securities shelf offering)
- AGIO -3.9% (prices offering of 8.25 mln shares of common stock at $31.00 per share)
- EQH -1.6% (announces sale of an aggregate of 144.0 mln shares of its common stock by AXA S.A. ), DB -1% (in sympathy with peer Credit Ag (-3%) after releases earnings)
Analyst comments:
- WORK -4% (initiated with Underperform at Wedbush)
- ALB -1.9% (downgraded to Underweight from Neutral at JP Morgan)
In reaction to strong earnings/guidance:
- SIEN +21.4%, FSLY +19.7%, STMP +19.4%, AAXN +17.6%, PAR +14.3%, EB +12.3%, ZG +11.3%, SWCH +10.8%, QNST +10.1% (also retains Goldman Sachs for review of strategic alternatives), AMPH +9.2%, PLNT +9.1% (also appoints Jeremy Tucker as Chief Marketing Officer, effective November 20), CORT +8.7%, YELP +8.6%, VSAT +8.6%, MTW +8.3%, GH +8.3%, FARM +7.7% (also discloses CFO change), GPRO +6.9%, LGF.A +6.4%, MIME +5.8%, DIS +5.7%, UEPS +5.2%, BKNG +4.8%, SWAV +4.3%, SGMS +4.3%, NCR +4.1%, CUTR +4.1%, MNST +4%, TROX +3.3%, AL +3%, AIRG +2.9%, ZIOP +2.7%, NET +2.6%, AMH +2.5%, REV +2.3%, RVLV +2.2%, CYRX +2.2%, CDAY +1.9% (CFO Arthur Gitajn to retire), ENB +1.6%, DBX +1.4%, NLOK +1.4%, AMCR +1.3%, AMBC +1.2%, WPRT +1%, HMC +1%
Other news:
- CFMS +15.7% (announces FDA clearance of next generation Conformis Hip System)
- IOVA +11.3% (presents new data from Cohort 2 of the ongoing Phase 2 lifileucel metastatic melanoma study)
- NK +10.1% (announces presentation of results from Phase 2 trial of natural killer cell-based therapeutic in metastatic Merkel cell carcinoma)
- PRTY +10% (modestly rebounding from yesterday's 67% decline)
- WKHS +4.2% (enters into intellectual property licensing agreement with Lordstown Motors Corp)
- EXEL +3.8% (collaborator Daiichi Sankyo reports positive results from Phase 3 pivotal trial of Esaxerenone)
- AIMT +2.2% (announces results from new analysis showing consistent efficacy and safety with AR101 across phase 3 PALISADE and ARTEMIS trials)
- MSG +0.9% (Madison Square Garden announces update regarding potential spin-off transaction; now pursuing full spin-off of entertainment businesses from sports businesses)
Analyst comments:
- TEX +3.8% (upgraded to Buy from Neutral at Goldman and added to Conviction Buy List)
- FL +2.2% (upgraded to Positive from Neutral at Susquehanna)
- ZIXI +1% (initiated with Outperform at Wedbush; tgt $10)
- MCD +0.9% (upgraded to Buy from Neutral at Longbow).
![]()